PTC Therapeutics Sees 2020 Duchenne Franchise Revenue $320M-$340M, Provides Corporate Update

- PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 - - 3 clinical trials from PTC's new redox platform to begin in 2020 - - ~ $306 million preliminary unaudited 2019 total revenue - - 2020

Benzinga · 01/13/2020 13:29

- PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020 -
- 3 clinical trials from PTC's new redox platform to begin in 2020 -
- ~ $306 million preliminary unaudited 2019 total revenue -
- 2020 Duchenne franchise revenue guidance of $320-340 million -